March 11, 2022 01:57 PM EST
Deals
Pharma

Fol­low­ing Vray­lar suc­cess, Ab­b­Vie ex­tends part­ner­ship with Gedeon Richter to neu­ropsy­chi­atric dis­eases

Nicole DeFeudis

Editor

Ab­b­Vie is see­ing dol­lar signs as it looks to ex­pand the la­bel on Vray­lar, its Gedeon Richter-part­nered an­tipsy­chot­ic block­buster. And now, it wants to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

A service from the Financial Times